Evidence map›Paper›PMID 40162805›Full record

ArticleJournal of clinical microbiology2025

Multi-center evaluation of the Selux next-generation phenotyping system for gram-negative direct-from-positive blood culture antimicrobial susceptibility testing.

Vincent Streva, Joseph Gajewski, Jacqueline Pento, Alamelu Chandrasekaran, Matt Green, Jill Lindley, Micahel Huband, Asmae El Ganbour, Kristen Roberts, Kelly Flentie and 3 more

Abstract readMulticenter StudyEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vincent StrevaNorthwell Heath, New York, New York, USA.ORCID 0009-0004-6306-7517
Joseph GajewskiElement, Acton, Massachusetts, USA.
Jacqueline PentoNorthwell Heath, New York, New York, USA.
Alamelu ChandrasekaranThe Center for Advanced Laboratory Medicine, Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0009-0005-6144-1533
Matt GreenElement, Acton, Massachusetts, USA.
Jill LindleyElement Iowa City (JMI Laboratories), North Liberty, Iowa, USA.
Micahel HubandElement Iowa City (JMI Laboratories), North Liberty, Iowa, USA.
Asmae El GanbourSelux Diagnostics, Charlestown, Massachusetts, USA.
Kristen RobertsSelux Diagnostics, Charlestown, Massachusetts, USA.
Kelly FlentieSelux Diagnostics, Charlestown, Massachusetts, USA.
Jingzi ShermanSelux Diagnostics, Charlestown, Massachusetts, USA.
Eric SternSelux Diagnostics, Charlestown, Massachusetts, USA.ORCID 0000-0001-9039-3693
Gregory J BerryThe Center for Advanced Laboratory Medicine, Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0002-0767-6826

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate and rapid antimicrobial susceptibility test (AST) results from positive blood cultures are crucial for patient care and combatting antimicrobial resistance. Although recent advancements in rapid direct-from-positive blood culture (PBC) identification platforms have enabled the provision of species-level identification and some resistance marker information within hours after blood culture positivity, AST results required for clinical decision-making often require 48 h after blood culture positivity. This study evaluated the Selux next-generation phenotyping system, including an automated PBC Separator and the Selux AST system in a multicenter clinical trial for their ability to perform AST directly from PBCs for gram-negative bacilli. The PBC separator produces McFarland equivalent inocula from positive blood cultures within 1 h, facilitating direct processing on the Selux AST system. The study evaluated 162 fresh clinical PBC samples, 307 seeded clinical samples, and 87 seeded challenge samples across 4 sites for each of the 17 antimicrobials included in the panel. The results demonstrate that the Selux system's clinical performance, reproducibility, and analytical performances are consistent when using positive blood cultures held for up to 16 h after positivity on the BACTEC and BacT/ALERT 3D and BacT/ALERT VIRTUO blood culture systems, including all major BACTEC and BacT/ALERT blood culture bottle types. These findings suggest that the PBC Separator with the Selux AST system is a valuable addition to the arsenal of tools available for rapid sepsis diagnosis and management.IMPORTANCETechnologies that consistently and substantially shorten the time between blood bottle positivity, organism identification, and complete AST results are crucial for ensuring that antimicrobial therapy can be tailored. The Selux PBC Separator and the Selux AST system perform rapid AST directly from positive blood culture bottles. This substantially shortens the gap between obtaining a positive blood bottle and organism identification and the availability of a fully actionable AST result.

Indexed as

Anti-Bacterial AgentsBacteremiaBlood CultureGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansMicrobial Sensitivity TestsPhenotypeReproducibility of ResultsAnti-Bacterial Agentsantimicrobial susceptibility testblood culturemulti-drug resistancerapid diagnostics

Identifiers

PMID40162805
PMCPMC12077214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.